Welcome to our dedicated page for Bioatla news (Ticker: BCAB), a resource for investors and traders seeking the latest updates and insights on Bioatla stock.
BioAtla, Inc. (Nasdaq: BCAB) is a global clinical-stage biotechnology company developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumors, and its news flow reflects the progress of this platform. Company announcements regularly describe updates on CAB-based antibody-drug conjugates and bispecific T-cell engagers, regulatory interactions, financing arrangements, and strategic collaborations.
Recent BioAtla news has highlighted the clinical and regulatory path for ozuriftamab vedotin (Oz-V), a CAB-Platform ROR2-targeting ADC. Releases describe compelling Phase 2 data in HPV-positive oropharyngeal squamous cell carcinoma (OPSCC), FDA Fast Track Designation for certain squamous cell carcinoma of the head and neck patients, and FDA alignment on a randomized Phase 3 trial design with dual primary endpoints. Additional coverage explains a special purpose vehicle (SPV) transaction with Inversagen AI, LLC and GATC Health Corp. intended to fund a registrational Oz-V trial in OPSCC while BioAtla retains a majority ownership interest in the Oz-V asset.
News items also focus on mecbotamab vedotin (Mec-V), a CAB AXL-targeting ADC in Phase 2 development, including clinical data in treatment-refractory soft tissue sarcomas and mKRAS non-small cell lung cancer. For BA3182, a CAB EpCAM x CAB CD3 bispecific T-cell engager, BioAtla has reported preliminary Phase 1 results in metastatic adenocarcinoma patients, describing a manageable safety profile and prolonged tumor control at higher dose levels.
Investors following BCAB news will also see regular updates on financial results, cash runway, and capital structure. The company has announced Pre-Paid Advance Agreements and a Standby Equity Purchase Agreement that provide flexible equity-linked financing, as well as a special meeting of stockholders to consider approval of potential share issuances and a possible reverse stock split. Additional releases discuss Nasdaq listing compliance milestones, patent coverage, and licensing agreements such as the worldwide license to Context Therapeutics for a CAB Nectin-4 x CD3 T-cell engager.
For those tracking oncology pipelines, regulatory milestones, and financing developments in clinical-stage biotech, the BioAtla news page offers ongoing detail on how the CAB platform and its lead programs are progressing. Investors and observers can use this stream of press releases to monitor trial design decisions, data presentations at major medical congresses, partnership activity and key corporate events related to BCAB stock.
BioAtla (Nasdaq: BCAB) will host a conference call on November 3, 2022, at 4:30 p.m. ET to discuss its financial results for Q3 2022 and provide business highlights. The press release with these results will be available prior to the call, and a replay will be accessible afterward. BioAtla focuses on Conditionally Active Biologic antibody therapeutics aimed at treating solid tumors. The company boasts an extensive patent portfolio with over 600 patents, and it is advancing two first-in-class CAB programs currently in Phase 2 clinical trials.
Himalaya Therapeutics has reported promising interim results for its clinical trial of HTBA3011 in Non-Small Cell Lung Cancer (NSCLC) and certain sarcomas. The trial shows an objective response rate of 43% in non-squamous NSCLC patients and 50% partial responses in undifferentiated pleomorphic sarcoma patients. As a result, the company plans to advance NSCLC to the registrational stage and proceed with Phase 2 enrollment for sarcomas. This success underlines the potential of Himalaya's Conditionally Active Biologics technology in addressing significant unmet medical needs.
BioAtla, Inc. (Nasdaq: BCAB) reported promising preliminary observations from its Phase 2 study of mecbotamab vedotin (BA3011) in non-small cell lung carcinoma (NSCLC). The candidate demonstrated a 33% objective response rate (ORR) in evaluable NSCLC patients. The company anticipates full interim data by 4Q22 and plans to initiate additional studies in undifferentiated pleomorphic sarcoma and osteosarcoma. With a cash balance of $202.3 million, BioAtla expects funding to last into 2H24, supporting continued clinical development across multiple programs.
BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biotechnology company, announced its participation in the 2022 BTIG Biotechnology Conference. The fireside chat is scheduled for August 8, 2022, at 12:00 p.m. ET in New York, NY. BioAtla specializes in Conditionally Active Biologic (CAB) therapeutics for treating solid tumors, featuring products in Phase 2 clinical testing, including mecbotamab vedotin and ozuriftamab vedotin. The company holds more than 600 patents, enhancing its innovative CAB technology and product candidates.
BioAtla (BCAB) announced a conference call on August 9, 2022, at 4:30 p.m. ET to discuss its Q2 2022 financial results and recent business highlights. The call will be accessible via webcast and telephone. BioAtla focuses on Conditionally Active Biologic (CAB) therapies for solid tumors, with two CAB programs in Phase 2 clinical trials and one in Phase 1/2. The company boasts over 500 patents covering its technology, emphasizing its innovative approach to antibody therapeutics aimed at increasing efficacy while reducing toxicity.
BioAtla, a clinical-stage biotechnology firm, announced a corporate update and one-on-one investor meetings at the Jefferies Global Healthcare Conference in New York, scheduled for June 8-10, 2022. CEO Jay M. Short and President Scott Smith will present on June 8 at 10:00 a.m. ET. The event will feature formal remarks and a webcast available on the company's website. BioAtla is known for its Conditionally Active Biologic (CAB) technology, with two CAB programs currently in Phase 2 testing.
BioAtla, Inc. (BCAB) reported significant progress in its clinical trials, with top-line interim data from the Phase 2 study of Mecbotamab vedotin (BA3011) in sarcoma showing promising results. Partial responses were noted in 33% of undifferentiated pleomorphic sarcoma patients, while the progression-free survival (PFS) rate reached 67% in osteosarcoma patients. The company ended Q1 2022 with a cash balance of $219.4 million, expected to fund operations into mid-2024. First quarter net loss was $24.3 million, an increase from $18.7 million in Q1 2021.
BioAtla, Inc. (Nasdaq: BCAB) announced a conference call on May 4, 2022, at 4:30 p.m. ET to discuss Q1 2022 financial results and provide topline data from the Phase 2 study of mecbotamab vedotin (BA3011) in sarcoma. The call will include updates on ongoing clinical programs like BA3011, ozuriftamab vedotin (BA3021), and CAB-CTLA-4 (BA3071). The press release with financial results will be available before the call on the company’s website.
BioAtla, Inc. (Nasdaq: BCAB) reported its Q4 and full-year 2021 financial results, revealing a net loss of $95.4 million, up from $35.9 million in 2020. R&D expenses surged to $58.3 million, reflecting ongoing clinical trials and development activities. The company maintains a strong cash position with $245 million, expected to fund operations through mid-2024. BioAtla is advancing its lead candidates, mecbotamab vedotin and ozuriftamab vedotin, into Phase 2 clinical trials, with interim updates anticipated in 2022. The company also plans to file INDs for several innovative product candidates.
BioAtla (Nasdaq: BCAB) announced a clinical collaboration with Bristol Myers Squibb (NYSE: BMY) to explore its lead candidates, BA3011 and BA3021, in combination with Opdivo (nivolumab) for solid tumors. BioAtla will sponsor the trials and bear execution costs, while Bristol Myers Squibb will supply Opdivo. Both candidates target AXL and ROR2, which are significant in various cancers, especially after prior anti-PD-1 therapy. This collaboration aims to enhance treatment options for patients with unmet medical needs.